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Purpose: To analyze the biochemical recurrence-free and cancer-specific survival after 
radical prostatectomy in a consecutive series of patients with prostate cancer.
Materials and Methods: We retrospectively reviewed data for 1,822 patients who under-
went radical prostatectomy with pelvic lymph node dissection at our institution be-
tween 1990 and 2009. After excluding 498 patients who were treated with neoadjuvant 
androgen deprivation therapy or who were followed up for ≤6 months, we included 1324 
patients (mean age, 64.4 years; mean prostate-specific antigen [PSA] level, 12.3 ng/ml). 
We assessed patient age at the time of surgery, preoperative PSA concentration, biopsy 
and pathologic Gleason scores, pathologic stage, surgical margin status, disease pro-
gression, and survival.
Results: The mean follow-up time was 40 months (range, 6-193 months). The 5- and 
10-year biochemical recurrence-free survival rates were 73.2% and 66.2%, respectively, 
and the 10-year cancer-specific survival rate was 92.4%. The mean time from surgery 
to biochemical recurrence was 18 months. In the multivariate analysis, Gleason score 
(4+3 vs. 2-6, p=0.004; 8-10 vs. 2-6, p＜0.001), pathologic stage (pT3a vs. pT2, p=0.001; 
pT3b-4 vs. pT2, p＜0.001; pN1 vs. pT2, p＜0.001), and resection margin status (p
＜0.001) were statistically significant predictors of biochemical recurrence, with only 
pathologic stage (pT3b-4 vs. pT2, p=0.006; pN1 vs. pT2, p=0.010) being a statistically 
significant predictor of cancer-specific survival.
Conclusions: Radical prostatectomy resulted in favorable cancer control in more than 
70% of patients after 5 years and a low (＜10%) cancer-specific mortality rate after 10 
years. The factors predictive of biochemical recurrence were Gleason score, pathologic 
stage, and resection margin status.
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INTRODUCTION
Prostate cancer is the most frequently detected cancer in 
males and is the second leading cause of cancer-related 
death among men in the United States [1]. The widespread 
use of prostate-specific antigen (PSA) as a diagnostic mark-
er has enabled prostate cancer to be diagnosed in younger 
patients, in patients with lower PSA concentrations, and 
in a higher proportion of patients with organ-confined dis-
ease, thus reducing the death rate by 20% [2,3]. Large var-
iations in the incidence of and mortality from prostate can-
cer have been observed among countries and racial/ethnic 
groups, with the lowest incidence seen among Asian men 
[4]. Similarly, various clinicopathologic characteristics of 
prostate cancer have been described in different ethnic 
groups. In Korea in 2007, prostate cancer was the fifth most 
common cancer among men, with an incidence of 21.5 per 
100,000 men [5]. We found that a significant proportion of 
prostate cancers in Korean men are poorly differentiated, 
regardless of initial serum PSA level or clinical stage at pre-
sentation; such poorly differentiated tumors adversely af-
fect prognosis, causing a greater rate of PSA failure [6]. Korean J Urol 2010;51:836-842
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TABLE 1. Patient clinical and demographic characteristics
Variables Value (%)
Age (yr)
　≤60 342 (25.8)
　61-65 333 (25.2)
　66-69 362 (27.3)
　≥70 287 (21.7)
Preoperative PSA level (ng/ml)
　≤3.9 90 (6.8)
　4.0-9.9 733 (55.4)
　≥10.0 495 (37.4)
Gleason score
　2-6 312 (23.6)
　3＋4 400 (30.2)
　4＋3 292 (22.1)
　8-10 319 (24.1)
Pathologic stage
　pT2N0 814 (61.5)
　pT3aN0 307 (23.2)
　pT3b-4N0 123 (9.3)
　pTanyN1 80 (6.0)
Resection margin
　Negative 922 (69.6)
　Positive 402 (30.4)
PSA: prostate-specific antigen
FIG. 1. Biochemical recurrence-free and cancer-specific survival in patients after radical prostatectomy. BCRFS: biochemical 
recurrence-free survival, CSS: cancer-specific survival.
Radical prostatectomy (RP) is the treatment of choice for 
men with localized prostate cancer [7,8]. In addition, sur-
geons can now anatomically dissect the prostate, thus re-
ducing perioperative morbidity during and after RP [9]. 
　In recent years, the number of RPs has increased dra-
matically in Korea, but the prognosis after RP has not been 
reported in Korean men. Here we update the follow-up data 
on our large series of patients who were treated by RP. We 
report the 20-year outcomes of 1,324 consecutive men who 
underwent RP for prostate cancer at our institution be-
tween 1990 and 2009. 
MATERIALS AND METHODS
We retrospectively reviewed data on 1,822 patients who 
underwent RP with pelvic lymph node dissection at our in-
stitution between 1990 and 2009. After excluding 498 pa-
tients who received neoadjuvant androgen deprivation 
therapy or who were followed up for 6 months or less, we 
included 1,324 patients (mean age, 64.4 years; mean PSA 
concentration, 12.3 ng/ml). We assessed patient age at the 
time of surgery, preoperative PSA level, Gleason scores (of 
biopsy and pathological specimens), pathologic stage (2002 
TNM stage), surgical margin status, disease progression 
(biochemical and clinical), and survival. Preoperative eval-
uation included magnetic resonance imaging (MRI) and 
bone scanning. PSA concentration was measured by im-
munoradiometry with 
125I-IRMA kits (CIS Bio Internatio-
nal, Gif-Sur-Yvette, France).
　Biopsy results indicated that RP was the first choice of 
curative treatment, regardless of Gleason score (GS). Pa-
tients underwent either open retropubic or robot-assisted 
laparoscopic RP, as determined by the treating surgeon. 
　RP specimens were examined microscopically after his-
tological sectioning at multiple levels when routine fix-
ation was concluded. Briefly, each surgical specimen was 
weighed and the external surface covered in India ink be-
fore fixing in 10% formalin. The prostate gland and seminal 
vesicles were step-sectioned perpendicular to the apical- 
basal axis. All lymph nodes were analyzed by routine paraf-
fin sectioning, in addition to evaluation of previous frozen 
sections. Tumor differentiation was evaluated by surgical 
Gleason scoring according to WHO consensus conference 
recommendations [10]. Surgical margins were considered 
positive when tumor foci were found by microscopy. 
　All patients were seen 3 and 6 months after surgery, and 
at least once yearly thereafter. Each visit included a clinical 
examination and PSA measurement. Biochemical recur-
rence was defined as any increase in PSA concentration ＞
0.2 ng/ml, determined more than 1 month postoperatively, 
and increasing on at least two subsequent occasions, or Korean J Urol 2010;51:836-842
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FIG. 2. Biochemical recurrence-free and cancer-specific survival after radical prostatectomy by clinicopathological factors. PSA: 
prostate-specific antigen.
when adjuvant therapy was required for advanced disease.
　Fisher’s exact test was used to compare percentage fre-
quencies, and Student’s t-test was used to compare means. 
Cancer-specific survival (CSS) and biochemical recurrence- 
free survival (BCRFS) were analyzed by the Kaplan-Meier 
method and were compared by the log-rank test. Prognostic 
factors were identified by univariate analysis, and those 
that were significant were entered into multivariate analy-
sis by using Cox’s regression method. A p-value less than 
0.05 was considered significant. All statistical analyses 
were performed by using SPSS ver. 11.5 (SPSS Inc., Chica-
go, IL, USA).
RESULTS
The clinical and pathologic characteristics of the 1,324 in-Korean J Urol 2010;51:836-842
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FIG. 2. Continued.
FIG. 3. Biochemical recurrence-free survival in patients with 
insignificant prostate cancer according to age (≤60 years, ≥61 
years).
cluded patients are summarized in Table 1. Of these, 342 
(25.8%) were aged 60 years or younger, and 90 (6.8%) had 
serum PSA concentrations below 4.0 ng/ml. Moreover, 814 
patients (61.5%) had localized prostate cancer and 80 
(6.0%) had lymph node invasion. GSs were 8 or higher in 
more than 24% of patients and were 2 to 6 in fewer than 
24%. Positive resection margins were observed in 402 pa-
tients (30.4%). 
　All patients were followed up for at least 6 months (mean, 
40 months; range, 6-193 months). The 5- and 10-year 
BCRFS rates were 73.2% and 66.2%, respectively, and the 
10-year CSS rate was 92.4%. The mean time from surgery 
to biochemical recurrence was 18 months (Fig. 1).
　When the patients were divided by age into four groups, 
those aged ≤60 years, 61-65 years, 66-69 years, and ≥70 
years, the 5- and 10-year BCRFS rates and the 10-year CSS 
rates did not differ significantly (Fig. 2A). A total of 316 pa-
tients who underwent RP had insignificant prostate can-
cer, as defined by Epstein et al [11] (clinical stage ≤T1c, 
PSA density ＜0.15 ng/ml/ml, biopsy GS ≤6, and number 
of positive cores ≤2). A total of 94 (29.4%) patients were 
younger than 60 years and 222 (70.3%) were older than 61 
years. There was a trend for a higher rate of insignificant 
prostate cancer in the age group younger than 60 years, but 
the difference was not statistically significant (≤60 years 
vs. ≥61 years, 27.6% vs. 22.6%, p=0.066). When comparing 
these two age groups, they were not significantly different Korean J Urol 2010;51:836-842
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TABLE 2. Multivariate analysis of factors significantly predictive
of biochemical recurrence
Multivariate
HR p-value 
Age (yr)  61-65 vs. ≤60 0.864 0.401 
66-69 vs. ≤60 0.843 0.338
≥70 vs. ≤60 0.705 0.060
Serum PSA 4.0-9.9 vs. ≤3.9 0.809  0.571 
  (ng/ml)  ≥10.0 vs. ≤3.9 1.305 0.473 
Gleason score  3＋4 vs. 2-6  1.496  0.222 
4＋3 vs. 2-6  2.406  0.004 
8-10 vs. 2-6  5.330  ＜0.001 
Pathologic stage  pT3aN0 vs. pT2N0  1.789  0.001 
pT3b-4N0 vs. pT2N0  2.585  ＜0.001 
pTanyN1 vs. pT2N0  4.176  ＜0.001 
Resection margin  Positive vs. Negative  1.709 ＜0.001 
HR: hazard ratio, PSA: prostate-specific antigen
TABLE 3. Multivariate analysis of factors significantly predictive
of cancer-specific survival
Multivariate
HR p-value 
Age (yr)  61-65 vs. ≤60 0.744 0.597 
66-69 vs. ≤60 0.368 0.133
≥70 vs. ≤60 0.547 0.324
Serum PSA 4.0-9.9 vs. ≤3.9 0.575  0.650
  (ng/ml)  ≥10.0 vs. ≤3.9 0.261 0.222 
Gleason score  2-6  -  - 
3＋4 -  - 
8-10 vs. 4＋3 4.348  0.054 
Pathologic stage  pT3aN0 vs. pT2N0  6.147  0.120 
pT3b-4N0 vs. pT2N0  20.803   0.006 
pTanyN1 vs. pT2N0  18.222 0.010 
Resection margin  Positive vs. Negative  1.910 0.242 
HR: hazard ratio, PSA: prostate-specific antigen
regarding pathologic GS, pathologic stage, or positive re-
section margin (p＞0.05). There were no significant differ-
ences in patients with upgraded prostate cancer (pathologic 
GS ≥7; 42.6% vs. 51.4%), patients with advanced prostate 
cancer (pathologic stage ≥T3a; 17.0% vs. 22.1%), or BCRFS 
rates between the two age groups (p＞0.05) (Fig. 3).
　However, poorly differentiated tumors were significan-
tly more common in patients aged ≥70 years than in those 
aged ≤60 years (GS 8-10: 22.5% in ≤60 years and 28.9% 
in ≥70 years). Grouping of patients by preoperative PSA 
concentration showed that the 5-year BCRFS rate was sig-
nificantly lower in patients with PSA levels ≥10 ng/ml 
than in those with PSA ＜10 ng/ml (56.7% vs. 84.8%, p＜ 
0.001), but the 10-year CSS rates did not differ significantly 
(89.8% vs. 95.5%, p=0.111) (Fig. 2B).
　Grouping of patients by pathologic GSs showed that the 
5-year BCRFS rates in patients with tumors classified as 
GS 2-6, 3＋4, 4＋3, and 8-10 were 91.3%, 86.8%, 74.8%, and 
44.0%, respectively (p＜0.001). None of the men with tu-
mors classified as GS ≤3＋4 died from prostate cancer, 
whereas those with a GS of 8-10 had a 10-year CSS rate of 
83.2% (p＜0.001) (Fig. 2C).
　The 5-year BCRFS and 10-year CSS rates were 86.6% 
and 99.3%, respectively, in patients with tumors classified 
as pathologic stage pT2; 61.2% and 91.4%, respectively, in 
patients with tumors classified as pT3a; 40.0% and 76.1%, 
respectively, in patients with tumors classified as pT3b-4; 
and 25.5% and 74.0%, respectively, in patients with tumors 
classified as pN1 (p＜0.001) (Fig. 2D). Although the 5-year 
BCRFS rates decreased gradually with pathologic stage, 
the 10-year CSS rates were considerably lower in patients 
with seminal vesicle or lymph node invasion than for other 
patients.
　We found that the 5-year BCRFS (54.5% vs. 81.4%, p＜ 
0.001) and 10-year CSS (83.9% vs. 96.6%, p＜0.001) rates 
were significantly lower in patients with positive than in 
those with negative surgical margins (Fig. 2E).
　Table 2 and 3 show the multivariate Cox’s regression 
analyses of factors predictive of biochemical recurrence 
and CSS. In the multivariate analysis, GS (4＋3 vs. 2-6, 
p=0.004; 8-10 vs. 2-6, p＜0.001), pathologic stage (pT3a vs. 
pT2, p=0.001; pT3b-4 vs. pT2, p＜0.001; pN1 vs. pT2, p
＜0.001), and resection margin status (p＜0.001) were stat-
istically significant predictors of biochemical recurrence, 
whereas only pathologic stage (pT3b-4 vs. pT2, p= 0.006; 
pN1 vs. pT2, p=0.010) was a statistically significant pre-
dictor of CSS.
DISCUSSION
We describe here the clinical characteristics and outcomes 
of a large cohort of men who underwent RP for prostate 
cancer. We found that 61.5% of our patients had organ-con-
fined disease, 23.2% showed extracapsular extension, 
9.3% had seminal vesicle invasion, and 6.0% had lymph 
node metastases, findings that are similar to previous re-
sults from our hospital [12] and also to those reported by 
others [13,14]. We found, however, that the percentage of 
men with a preoperative PSA concentration ＜4 ng/ml and 
a pathologic GS of 2-6 was lower (6.8% and 23.6%, re-
spectively) than in earlier studies (18-28.1% and 46.1-69%, 
respectively) [13-17]. Although PSA range distribution 
and GS have varied from study to study, about 60% of 
Western men had GSs of 2-6 and more than 70% of those 
in a recent study had GSs ≥7. The GS distributions in stud-
ies of Asian patients were similar, with 46.7% of Chinese 
and 56.2% of Japanese patients having GSs ≥7 [18,19]. We 
have already reported on this discrepancy among ethnic 
groups [6]. The results presented here suggest that, stage- 
for-stage, prognosis may be similar in Westerners and 
Asians, except that Korean men may be at greater risk of 
biochemical relapse because more of their tumors are poor-Korean J Urol 2010;51:836-842
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ly differentiated.
　We found that the overall 10-year BCRFS was 66.2% and 
that fewer than 10% of our patients died of prostate cancer 
within 10 years of RP. Although these results confirm that 
RP affords excellent long-term cancer control, the rates 
were lower than seen in previous studies of large numbers 
of patients [14,15,17]. Preoperative PSA concentration, 
pathologic stage, and GS have been found to be factors pre-
dictive of prognosis in patients with prostate cancer who 
underwent RP [15]. Thus, the presence of a greater pro-
portion of patients with high-grade cancer in a study series 
may adversely affect surgical outcomes, especially after 
control for preoperative PSA and pathologic stage, as 
shown by the high BCRFS and CSS rates observed here.
　We found no difference in prognosis according to age. 
However, an earlier study suggested that younger men 
present with more treatable disease [20]. We found that a 
higher percentage of younger men had GSs of 2-6, whereas 
a greater percentage of older men had GSs of 8-10, although 
there was no between-group difference in prognosis. Indeed, 
compared with previous studies, which found that 50% and 
30% of patients had GSs of 2-6 and 7, respectively, fewer 
of our patients had GSs of 2-6 and more of our patients (＞
50%) had GSs of 7 [13-15,17]. We found, however, that the 
distribution of GSs did not differ with patient age. 
　PSA screening results in the detection of disease that is 
not clinically significant in many patients [21]. Recent 
studies have shown that there is a trend for a higher rate 
of preoperative insignificant prostate cancer in younger 
patients, but no difference in pathologic outcomes between 
the two age groups. We showed that age is not an important 
factor for disease-specific mortality in patients with insig-
nificant prostate cancer. Furthermore, pathologic GS ≥7 
and advanced prostate cancer was detected in more than 
40% and 17%, respectively, of younger patients with insig-
nificant prostate cancer, which indicates that patients 
with insignificant prostate cancer need definitive treat-
ment.
　Although a preoperative serum PSA concentration ≥10 
ng/ml was significantly associated with the risk of re-
currence, we found that, after controlling for tumor grade, 
stage, and margin status, PSA level was not predictive of 
recurrence. In contrast, previous studies found that pre-
treatment PSA concentration was one of the most pre-
dictive prognostic factors in patients undergoing RP [15]. 
Moreover, although biochemical progression-free survival 
rates were previously found to differ significantly between 
patients with PSA levels ＜4 ng/ml and ≥4 ng/ml [22], we 
did not observe such a difference in the current study. It 
may be relevant that, in the cited earlier report, 20% of pa-
tients had PSA ＜4 ng/ml, compared with 6.8% of our 
patients. Because PSA is highly associated with pathologic 
stage and GS, we suggest that PSA may not be a predictor 
of biochemical recurrence in multivariate analysis.
　Patients with Gleason stage 8-10 tumors had a 5-year bi-
ochemical recurrence rate exceeding 50% and a 10-year 
cancer-specific death rate of about 20%, which was thus 
higher than the 10% rate in patients with GSs of 7. After 
controlling for preoperative PSA concentration, pathologic 
stage, and resection margin status, we found that the risk 
of biochemical failure was ＞5-fold higher for patients with 
GSs of 8-10 than for those with GSs of 6. The biochemical 
failure rate did not differ significantly in patients with GSs 
of 6 and 3＋4, in contrast with previous findings, which re-
ported a statistically significant difference in recurrence 
rate between these two groups of patients [23]. In the cited 
study, 62% of patients had GSs of 2-6, including 17% with 
GSs of 2-5, compared with 23.6% of our patients. Intere-
stingly, none of the men with GSs of 2-6 or 3＋4 died of pros-
tate cancer.
　The 5-year BCRFS rate was ＜90% in patients with or-
gan-confined disease and approximately 60% in those with 
extracapsular extension disease, a 10% difference com-
pared with previous studies with large numbers of patients 
[14,23]. In contrast, the 5-year BCRFS rates of patients 
with seminal vesicle invasion and lymph node metastases 
were 40% and 25%, respectively, which is similar to those 
of previous studies. The differences are likely attributable 
to variation in the distributions of GSs. In previous studies, 
about 59% to 69% of patients had GSs of 6 [15,17,23], com-
pared with 23.6% of our patients, including 27.1% with or-
gan-confined disease and extracapsular extension.
　We found that 30.4% of our patients had positive surgical 
margins, higher than the 21.2% of patients in the Surveil-
lance, Epidemiology, and End Results (SEER) program da-
tabase [24]. However, the cited study included only pa-
tients with T2 and T3a prostate cancer, with 86.7% of pa-
tients being classified as T2. Pathologic stage has been as-
sociated with surgical margin status, with 17.7% of T2 pa-
tients and 43.8% of T3a patients in the SEER database hav-
ing positive margins; the surgical margin positivity rate we 
observed was only slightly higher. Many studies have dem-
onstrated an association between positive surgical mar-
gins and a higher rate of recurrence after radical prostatec-
tomy [24-26]. In agreement with these results, we found 
that a positive surgical margin was associated with in-
creased risks of biochemical recurrence and cancer-specific 
death on univariate analysis, but only with biochemical re-
currence on multivariate analysis. Compared to patients 
with negative surgical margins, the risk of biochemical re-
currence was 70% higher. Except for the SEER database 
study, no other report has found a significant association 
between positive surgical margins and cancer-specific 
mortality [24]. 
　We found that positive surgical margin, pathologic 
stage, and GS were predictive of biochemical recurrence in 
patients with prostate cancer who underwent RP, whereas 
only pathologic stage was predictive of cancer-specific 
mortality. Because more than 60% of our patients under-
went RP over the last 4 years, our follow-up period is cur-
rently too short to evaluate long-term, cancer-specific mor-
tality after RP.
　Our study had several important limitations. Our find-
ings represent outcomes from a single institution, over 20 Korean J Urol 2010;51:836-842
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years, and describe the work of eight surgeons who, be-
tween them, performed 1,822 consecutive radical prosta-
tectomies. Thus, patient selection and surgical technique 
may have differed over time, and cancer control rates may 
have varied somewhat. However, two surgeons (H. A. and 
C. S. K.) performed over 90% of the RP procedures delivered 
during our reporting period, thus reducing the probability 
of surgery-associated variation. In addition, the mean fol-
low-up period of our patients was only 40 months. Further 
evaluation is needed to determine the long-term rates of 
CSS and metastatic progression.
CONCLUSIONS
The present study, which presented our intermediate re-
sults on work with a large number of Korean patients who 
underwent RP, shows that long-term PSA recurrence out-
comes after RP remain suboptimal, because nearly 50% of 
men are at risk for PSA recurrence 15 years after surgery. 
However, our CSS outcomes were excellent, in that about 
90% of men remained alive 5 years after surgery. Because 
favorable cancer control was associated with negative sur-
gical margins, complete resection during prostatectomy for 
prostate cancer remains important.
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